Author:
Imanpour Aylar,Kolahi Azar Hanieh,Makarem Dorna,Nematollahi Zeinab,Nahavandi Reza,Rostami Mohammadreza,Behestizadeh Nima
Abstract
AbstractOsteoporosis is a bone condition characterized by reduced bone mineral density (BMD), poor bone microarchitecture/mineralization, and/or diminished bone strength. This asymptomatic disorder typically goes untreated until it presents as a low-trauma fracture of the hip, spine, proximal humerus, pelvis, and/or wrist, requiring surgery. Utilizing RNA interference (RNAi) may be accomplished in a number of ways, one of which is by the use of very tiny RNA molecules called microRNAs (miRNAs) and small interfering RNAs (siRNAs). Several kinds of antagomirs and siRNAs are now being developed to prevent the detrimental effects of miRNAs. The goal of this study is to find new antagonists for miRNAs and siRNAs that target multiple genes in order to reduce osteoporosis and promote bone repair. Also, choosing the optimum nanocarriers to deliver these RNAis appropriately to the body could lighten up the research road. In this context, we employed gene ontology analysis to search across multiple datasets. Following data analysis, a systems biology approach was used to process it. A molecular dynamics (MD) simulation was used to explore the possibility of incorporating the suggested siRNAs and miRNA antagonists into polymeric bioresponsive nanocarriers for delivery purposes. Among the three nanocarriers tested [polyethylene glycol (PEG), polyethylenimine (PEI), and PEG-PEI copolymer], MD simulations show that the integration of PEG-PEI with has-mIR-146a-5p is the most stable (total energy = -372.84 kJ/mol, Gyration radius = 2.1084 nm), whereas PEI is an appropriate delivery carrier for has-mIR-7155. The findings of the systems biology and MD simulations indicate that the proposed RNAis might be given through bioresponsive nanocarriers to accelerate bone repair and osteoporosis treatment.
Publisher
Springer Science and Business Media LLC
Reference70 articles.
1. Wright, N. C. et al. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J. Bone Miner. Res. 29(11), 2520–2526 (2014).
2. Fusco, A. Is multidisciplinary rehabilitation effective for individuals with hip fractures?—A Cochrane Review summary with commentary. J. Musculoskelet. Neuronal Interact. 23(1), 1 (2023).
3. Lam, P. Y., Cheung, P. W. H., Lau, S. T. & Cheung, J. P. Y. Quality of life of postmenopausal women with teriparatide, denosumab and alendronate: One-year prospective study with a propensity score-matched comparison. J. Orthopaed. Trauma Rehabil. 30(1), 22104917221136280 (2023).
4. Hung, T. N. K. et al. An AI-based prediction model for drug–drug interactions in osteoporosis and Paget’s diseases from SMILES. Mol. Inform. 41(6), 2100264 (2022).
5. Rocho, F. R. et al. A patent review on cathepsin K inhibitors to treat osteoporosis (2011–2021). Exp. Opin. Ther. Patents 32(5), 561–573 (2022).
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献